SESSION TYPE: Lung Cancer II
PRESENTED ON: Monday, October 22, 2012 at 04:00 PM - 05:30 PM
PURPOSE: TAMs are a major component of a tumor. They produce high amounts of interleukin (IL)-10 but not IL-12, express high levels of angiogenesis factor, such as VEGF, PDGF, COX-2. TAMs also produced potent cytokines, such as MMP-9, uPA, cathepsin B, to promote cancer cells invasion and metastasis. These factors generally accepted as the marker of TAM. The aim of our study was to study the prognositic significance of TAM in non-small cell lung cancer.
METHODS: TAM was isolated from 63 primary non-small lung cancer tissues by short term cultivation in serum-free medium. The mRNA expression levels of TAM markers were analyzed using real-time PCR, compared with matched normal macrophages from the 63 patients. The relationships between those gene expression levels and clinicopathological features were investigated. The TAM markers expression levels was correlated with disease-free survival.
RESULTS: High levels of IL-10 in TAM significantly correlated with stage, lymph node metastasis, or histologic poor differentiation. The MMP-9 expression by TAMs were significantly higher in the late stage than the early stage. The marker IL-10, uPA and MMP-9 statistically significantly correlated with DFS (p<0.0001, p=0.011, p=0.022 respectively).
CONCLUSIONS: The results of this study demonstrated that those up-regulated genes in TAMs contributed to lung cancer. A statistically significant association between shorter DFS was also seen for the patients with IL-10 and MMP-9 expression in TAM, which suggested that phenotypic expression on TAMs, like MMP9, IL-10 can be potentially used to predict prognosis as well.
CLINICAL IMPLICATIONS: These data indicated that TAM expressed MMP-9 and IL-10 may contribute to tumor progression, and that they are useful prognostic markers in non-small cell lung cancer.
DISCLOSURE: The following authors have nothing to disclose: Rui Wang, Jie Zhang, Haiquan Chen
No Product/Research Disclosure InformationDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China